- Previous Close
2,252.85 - Open
2,254.00 - Bid --
- Ask --
- Day's Range
2,183.50 - 2,262.60 - 52 Week Range
1,368.25 - 2,402.90 - Volume
689,315 - Avg. Volume
997,935 - Market Cap (intraday)
999.657B - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
38.17 - EPS (TTM)
57.41 - Earnings Date Feb 5, 2025 - Feb 10, 2025
- Forward Dividend & Yield 8.00 (0.37%)
- Ex-Dividend Date Jul 16, 2024
- 1y Target Est
2,228.91
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
www.lupin.com19,210
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: LUPIN.NS
View MorePerformance Overview: LUPIN.NS
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LUPIN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LUPIN.NS
View MoreValuation Measures
Market Cap
999.38B
Enterprise Value
998.40B
Trailing P/E
38.17
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.78
Price/Book (mrq)
6.39
Enterprise Value/Revenue
4.76
Enterprise Value/EBITDA
21.01
Financial Highlights
Profitability and Income Statement
Profit Margin
12.26%
Return on Assets (ttm)
9.52%
Return on Equity (ttm)
18.27%
Revenue (ttm)
214.31B
Net Income Avi to Common (ttm)
26.26B
Diluted EPS (ttm)
57.41
Balance Sheet and Cash Flow
Total Cash (mrq)
29.12B
Total Debt/Equity (mrq)
21.90%
Levered Free Cash Flow (ttm)
11.56B